Fig. 3From: Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)LS mean change in (a) SGRQ, (b) CAT and (c) CCQ from baseline for health outcomes assessments. For each health outcomes assessment, all treatment groups showed statistically significant (p < 0.05) changes from baseline at all time points. CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; ITT, intent-to-treat; LS, least squares; REV, revefenacin; SE, standard error; SGRQ, St. George’s Respiratory Questionnaire; TIO, tiotropiumBack to article page